Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) Research & Development (2020 - 2024)

Immuneering has reported Research & Development over the past 5 years, most recently at $14.9 million for Q4 2024.

  • Quarterly results put Research & Development at $14.9 million for Q4 2024, up 24.74% from a year ago — trailing twelve months through Dec 2024 was $48.0 million (up 15.23% YoY), and the annual figure for FY2025 was $42.0 million, down 12.33%.
  • Research & Development for Q4 2024 was $14.9 million at Immuneering, up from $11.3 million in the prior quarter.
  • Over the last five years, Research & Development for IMRX hit a ceiling of $14.9 million in Q4 2024 and a floor of $3.2 million in Q2 2020.
  • Median Research & Development over the past 5 years was $9.4 million (2022), compared with a mean of $8.7 million.
  • Biggest five-year swings in Research & Development: skyrocketed 117.07% in 2021 and later increased 7.33% in 2023.
  • Immuneering's Research & Development stood at $4.9 million in 2020, then soared by 62.57% to $8.0 million in 2021, then grew by 24.17% to $9.9 million in 2022, then grew by 20.65% to $11.9 million in 2023, then increased by 24.74% to $14.9 million in 2024.
  • The last three reported values for Research & Development were $14.9 million (Q4 2024), $11.3 million (Q3 2024), and $10.7 million (Q2 2024) per Business Quant data.